Neuraltus scores $17M to treat degenerative brain disease
Neuraltus Pharmaceuticals, developer of drugs used to treat degenerative neurological diseases, brought in $17 million in a first round of funding from Latterell Venture Partners, VantagePoint Venture Partners and Adams Street Partners. The Menlo Park, Calif.-based company says it’s currently working on therapies for conditions ranging from Lou Gehrig’s Disease to Parkinson’s Disease.
The money should be enough to push drugs for both these diseases through the first two phases of clinical trials, Neuraltus says.
Next Story: Barosense looks to raise $30M to market obesity device
Previous Story: Tesla unveils electric sedan with sky-high hopes
About the Author, Camille Ricketts
Camille is the lead writer for GreenBeat. She came to VentureBeat from Google where she worked on its traditional platforms team, particularly in TV. Before that, she was a reporter for the Wall Street Journal in New York and London. Follow her on Twitter at @camillericketts, and follow VentureBeat on Twitter at @venturebeat.
With GreenBeat 2009, VentureBeat's all-star conference on all things Smart Grid, coming up in November, Camille will be expanding coverage of this exciting space. Stay up to date by following @greenbeat2009 on Twitter or by becoming a fan of the event on Facebook here.